Asia’s Largest Web3 Event TOKEN2049 Singapore Announces Title Sponsors
7.6.2022 09:37:00 EEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, has announced a number of high profile Title Sponsors for its much-anticipated Singapore debut. Taking place from 28-29 September 2022, this year’s event marks TOKEN2049’s first physical presence in Singapore, which will be held in conjunction with the Formula 1 Singapore Grand Prix 2022, ahead of the race weekend.
As the flagship event of Asia Crypto Week, the conference is set to see over 3,000 attendees as they gather to learn from prominent thought leaders and innovators across the crypto industry, including the CEOs and founders of some of the world’s largest crypto-related projects. Over 130 sponsors and exhibitors have already confirmed their participation with numbers steadily rising as anticipation builds ahead of September.
“TOKEN2049 is shaping up well in bringing together the brightest minds of our ecosystem in exploring pathways of innovation and collaboration. As one of the leading enablers dedicated to unlocking the full potential of digital assets, we look forward to the dialogue and conversations at this gathering,” said Cynthia Wu, Founding Partner at Matrixport.
With this year’s agenda spanning institutional investment trends to the rise of the metaverse and Web3, the diversity of this year’s title sponsors for TOKEN2049 Singapore is a testament to a flourishing industry ecosystem. This includes Singapore-based crypto unicorn and digital assets financial services platform Matrixport; leading cryptocurrency exchange app and Formula 1 global partner Crypto.com; global leader in digital assets products and infrastructure Amber Group; revolutionary social currency $WHALE which is backed by one of the largest and most valuable NFT collections in the world; community-governed DeFi platform MantraDAO; and collaborative Web3 credential infrastructure Project Galaxy.
Celebrating the upcoming event, Raphael Strauch, Founder of TOKEN2049 said: “Within the past few months, the crypto ecosystem has seen a whirlwind of change and growth, and it’s only befitting that we’re gathering in Singapore — one of the region’s leading innovation hubs — to celebrate how far we’ve come.”
Alongside its impressive speaker line-up including Pantera Capital CEO Dan Morehead, Ava Labs CEO Emin Gün Sirer, Three Arrows Capital CIO and CEO Su Zhu. Additional title sponsors at the event include enterprise-grade crypto infrastructure company Fireblocks; cryptocurrency exchange and derivative trading platform Bitmex; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; decentralised and open-source platform Syscoin; Asia’s leading institutional digital asset custodian Hextrust; global online identity verification platform Trulioo; the blockchain platform TRON and the first official Ethereum Virtual Machine based on the EOS network Trust EVM.
“From our decorated bench of Title Sponsors to our speaker line-up, we’re thrilled to see continued support from so many of the industry’s leading organizations and are looking forward to spotlighting some of the most exciting, emerging voices across the ecosystem. We’ve seen tremendous interest from potential speakers and sponsors alike, and are thrilled to deliver a top-notch conference experience for all. To that end, we are very excited to be hosting a large closing party CÉ LA VI Singapore, on the rooftop deck of the Marina Bay Sands, overlooking the F1 Grand Prix track, with several notable European DJs flying in to grace the event,” continued Strauch.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
Raphael Strauch, Founder of TOKEN2049 is available for interview.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606006051/en/
Contact information
Media:
Melissa Esguerra
Senior Consultant
Wachsman
melissa.esguerra@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom